Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease

Neuroscience Letters

Volumn 241, Issue 1, 1998, Pages 53-56

  Meßmer, Kirsten ^a   Reynolds, Gavin P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Huntington's disease; Inflammation; Peripheral type benzodiazepine binding sites

Indexed keywords

BENZODIAZEPINE RECEPTOR; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE;

ADULT; ARTICLE; BINDING SITE; CADAVER; CONTROLLED STUDY; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; RECEPTOR DENSITY; TEMPORAL CORTEX;

ADULT; AGED; BENZODIAZEPINES; BINDING SITES; BRAIN; FRONTAL LOBE; HUMANS; HUNTINGTON DISEASE; MIDDLE AGED; PUTAMEN; RADIOLIGAND ASSAY; TEMPORAL LOBE;

EID: 0344110538     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(97)00967-1     Document Type: Article

References (31)

1. Ball J.A., Burnet P.W., Bretherton-Watt D., Bloom S.R. Increase in diazepam binding inhibitor-like immunoreactivity (51-70) in Huntington's disease. J. Neurol. Sci. 88:1988;177-184.
2. Beal M.F., Hyman B.T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative disease? Trends Neurosci. 16:1992;125-131.
3. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
4. 3 site ligand: a critical analysis of animal models of cerebral ichaemia and neurodegeneration. Brain Res. 522:1990;275-289.
5. Benavides J., Fage D., Carter C., Scatton B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. 421:1987;167-172.
6. 3 (peripheral type benzodiazepine) binding sites in the rat cortex and striatum after local injection of interleukin 1, tumour necrosis factor alpha and lipopolysaccharide. Brain Res. 453:1991;194-200.
7. Bruyn, G.W., Bots, G.Th.A.M. and Dom, R., Huntington's chorea: current neuropathological status. In T.N. Chase, N.S. Wexler and A. Barbeau (Eds.), Advances in Neurology, Vol. 23, Raven, New York, 1979, pp. 83-93.
8. Canat X., Guillaumont A., Bouaboula M., Poinot-Chanzel C., Derocq J.M., Caryon P., LeFur G., Casellas P. Peripheral benzodiazepine receptor modulation with phagocytic differentiation. Biochem. Pharmacol. 43:1993;551-554.
9. Costa E., Guidotti A. Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. Life Sci. 49:1991;325-344.
10. Demerle-Pallardy C., Duverger D., Spinnewyn B., Pirotzky E., Braquet P. Peripheral type benzodiazepine binding sites following forebrain ischemia in the rat: effect of neuroprotective drugs. Brain Res. 565:1991;312-320.
11. Diori D., Welner S.A., Butterworth R.F., Meaney M.J., Suranyicadotte B.E. Peripheral benzodiazepine binding-sites in Alzheimer's disease frontal and temporal cortex. Neurobiol. Aging. 12:1991;255-258.
12. Dubois A., Benavides J., Peny B., Duverger D., Fage D., Gotti B., MacKenzie E.T., Scatton B. Imaging of primary and remote ischaemic and excitotoxic brain lesions. An autoradiographic study of peripheral type benzodiazepine sites in the rat and cat. Brain Res. 445:1988;70-90.
13. Ferrarese C., Appollonio I., Frigo M., Meregalli S., Piolti R., Tamma F., Frattola L. Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia. Neurology. 40:1990;632-635.
14. Groom G.N., Junck L., Foster N.L., Frey K.A., Kuhl D.E. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. J. Nucl. Med. 36:1995;2207-2210.
15. Heyes M.P., Achim C.L., Wiley C.A., Major E.O., Saito K., Markey S.P. Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 328:1996;595-597.
16. Heyes M.P., Saito K., Crowley J.S., Davis L.E., Demitrack M.A., Der M., Dilling L.A., Elia J., Kruesi M.J.P., Lackner A., Larsen S.A., Lee K., Leonard H.L., Markey S.P., Martin A., Milstein S., Mouradian M.M., Pranzatelli M.R., Quearry B.J., Salazar A., Smith M., Strauss S.E., Sunderland T., Swedo S.W., Tourtellotte W.W. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 115:1992;1249-1273.
17. Ishii T., Haga S. Immuno-electron microscopic localisation of immunoglobulins in amyloid fibrils of senile plaques. Acta Neuropathol. (Berlin). 36:1976;243-249.
18. Kowall N.W., Ferrante R.J., Martin J.B. Patterns of cell loss in Huntington's disease. Trends Neurosci. 10:1987;24-29.
19. Lange H., Thörner G., Hopf A., Schröder K.F.J. Morphometric studies of the neuropathological changes in choreatic diseases. Neurol. Sci. 28:1976;401-425.
20. Levivier M., Gash D.M., Przedborski S. Time course of neuroprotective effect of transplantation on quinolinic acid-induced lesions of the striatum. Neuroscience. 69:1995;43-50.
21. Mazurek M.F., Garside S., Beal M.F. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Ann. Neurol. 41:1997;540-547.
22. Pearson S.J., Reynolds G.P. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci. Lett. 144:1992;199-201.
23. Pearson S.J., Reynolds G.P. Neocortical neurotransmitter markers in Huntington's disease. J. Neural Transm. 98:1994;197-207.
24. Reynolds G.P., Pearson S.J., Halket J., Sandler M. Brain quinolinic acid in Huntington's disease. J. Neurochem. 50:1988;1959-1960.
25. Rogers J., Webster S., Lue L.F., Brachova L., Civin W.H., Emmerling M., Shivers B., Walker D., McGeer P. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging. 17:1996;681-686.
26. 3H]Ro5-4864 benzodiazepine binding in the kainate lesioned striatum and Huntington's disease basal ganglia. Brain Res. 248:1982;396-401.
27. Selkoe D.J., Salazar F.J., Abraham C., Kosik K.S. Huntington's disease: changes in striatal proteins reflect astrocytic gliosis. Brain Res. 245:1982;117-125.
28. The Huntington's disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell, 72 (1993) 971-983.
29. Töpper R., Gehrmann J., Schwarz M., Block F., Noth J., Kreutzberg G.W. Remote microglial activation in the quinolinic acid model of Huntington's disease. Exp. Neurol. 123:1993;271-283.
30. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Biol. 44:1987;559-577.
31. Woods M.J., Williams D.C. Multiple forms and locations for the peripheral-type benzodiazepine receptor. Biochem. Pharmacol. 52:1996;1805-1814.